Glatiramer acetate treatment in PPMS: why males appear to respond favorably.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Neurological Sciences

• Publication date

  2009-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jns.2009.04.019PMID 19426995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

  2009cited by this paper
• Gender-related differences in MS: a study of conventional and nonconventional MRI measures

  2009cited by this paper
• Multiple sclerosis relapses: a multivariable analysis of residual disability determinants

  2009cited by this paper
• INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

  2009cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  2008cited by this paper
• Disability as an outcome in MS clinical trials

  2008cited by this paper
• Intravenous immunoglobulin in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Contribution of relapses to disability in multiple sclerosis

  2008cited by this paper
• Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis

  2008cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Natural history of multiple sclerosis in a population‐based cohort

  2008cited by this paper
• Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study

  2008cited by this paper
• Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

  2007cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007influential reference
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  2006cited by this paper
• Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

  2006cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• Sex ratio of multiple sclerosis in Canada: a longitudinal study.

  2006cited by this paper
• MRI T2 lesion burden in multiple sclerosis

  2006cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Brain atrophy and lesion load in a large population of patients with multiple sclerosis

  2005cited by this paper
• Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials

  2005cited by this paper
• The natural history of primary progressive MS in British Columbia, Canada

  2005cited by this paper
• Nitric oxide: a potential inducer of adhesion-related apoptosis--anoikis.

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• The PRO MiSe trial: baseline data review and progress report

  2004cited by this paper
• Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis

  2004cited by this paper
• Interferon beta-1b in secondary progressive MS

  2004cited by this paper
• Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials

  2003cited by this paper
• The diagnosis of primary progressive multiple sclerosis.

  2003cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003cited by this paper
• ‘Gender gap’ in multiple sclerosis: magnetic resonance imaging evidence

  2003cited by this paper
• A controlled trial of natalizumab for relapsing multiple sclerosis.

  2003cited by this paper
• Interferon β-1a in primary progressive MS

  2003cited by this paper
• Effect of relapses on development of residual deficit in multiple sclerosis

  2003cited by this paper
• Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

  2003cited by this paper
• Two-year follow-up study of primary and transitional progressive multiple sclerosis

  2002cited by this paper
• The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

  2002cited by this paper
• A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

  2002cited by this paper
• Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

  2002cited by this paper
• Randomized, comparative study of interferon β-1a treatment regimens in MS

  2002cited by this paper
• Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses

  2002cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

  2001cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• TNF neutralization in MS

  1999cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

  1999cited by this paper
• TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study

  1999cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

  1987cited by this paper

• The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?

  2022cites this paper
• Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

  2020cites this paper
• Diagnosis and Management of Progressive Multiple Sclerosis

  2019cites this paper
• A case for gender-based approach to multiple sclerosis therapeutics.

  2018cites this paper
• Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis

  2018cites this paper
• Trials of Licenced RRMS DMTs in Progressive MS

  2018cites this paper
• Emerging drugs for primary progressive multiple sclerosis

  2018cites this paper
• Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review.

  2017cites this paper
• Clinical trial design for progressive MS trials

  2017cites this paper
• Sex/gender influences on the nervous system: Basic steps toward clinical progress

  2017cites this paper
• Sex-Related Factors in Multiple Sclerosis

  2016cites this paper
• The heritage of glatiramer acetate and its use in multiple sclerosis

  2016cites this paper
• Multiple sclerosis in men: management considerations

  2016cites this paper
• Investigating the role of Epstein-Barr virus in the pathogenesis of Multiple Sclerosis

  2015cites this paper
• Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

  2015influential citation
• The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis

  2014cites this paper
• Experiences of Iranian Multiple Sclerosis patients' and their caregivers' regarding care and treatment outcomes

  2014cites this paper
• Sexual disparities in the incidence and course of MS.

  2013cites this paper
• Treatment of Primary Progressive Multiple Sclerosis

  2013cites this paper
• Disease-modifying treatments for progressive multiple sclerosis

  2013cites this paper
• Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

  2013cites this paper
• Gender-related differences in multiple sclerosis patients

  2013cites this paper
• Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.

  2013cites this paper
• Sex affects immunity.

  2012cites this paper
• Interferon Beta and Glatiramer Acetate Therapy

  2012cites this paper
• Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

  2012cites this paper
• Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

  2012cites this paper
• Sex-related factors in multiple sclerosis susceptibility and progression

  2012cites this paper
• Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders

  2011cites this paper
• Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms.

  2011cites this paper
• Im Spannungsfeld von Wirkung und Nebenwirkung

  2011cites this paper
• Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis

  2010cites this paper
• Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.

  2010cites this paper
• Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis

  2010cites this paper
• Treating multiple sclerosis with monoclonal antibodies: a 2010 update

  2010cites this paper
• Gender Issues in Multiple Sclerosis: An Update

  2010influential citation
• Is multiple sclerosis a mitochondrial disease?

  2009cites this paper